ArticleEuropean journal of nuclear medicine and molecular imaging2025
Prognostic value of [
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Quantitative PSMA PET Biomarkers for Predicting Response toJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Pooled it
- Diagnostic value of dual-tracer PET/CT with [Frontiers in medicine · 2025Pooled it
- Baseline PSMA-ligand PET/CT as a predictive biomarker for early progression in metastatic castration-resistant prostate cancer patients undergoing [177Lu]Lu-PSMA-617 radioligand therapy.Annals of nuclear medicine · 2026Article
- Real-world outcomes of [European journal of nuclear medicine and molecular imaging · 2026Article
- Parametric imaging of dynamic long-axial-field-of-view PET scans: Technical challenges, statistical insights and clinical applications.Zeitschrift fur medizinische Physik · 2026Review
- Baseline PSMA PET/CT Biomarkers for Patient Selection in [Pharmaceuticals (Basel, Switzerland) · 2026Review
- When PSMA is not enough: the diagnostic blind spots of PSMA PET/CT and the added value of [¹⁸F]FDG in high-risk prostate cancer: dual-tracer cohort study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- The Prognostic Value ofAnnals of nuclear medicine · 2026Article
- Prognostic value of tumour volume based on [EJNMMI reports · 2026Article
- Tumour Microenvironment-Informed Radiotheranostics: Why and How Nuclear Medicine Could Advance Precision Oncology in the Decade Ahead.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617.European journal of nuclear medicine and molecular imaging · 2026Article
- FDG/PSMA discordance in [Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo improve [
methodsWe conducted a retrospective analysis in 152 mCRPC patients referred for LuPSMA therapy who underwent PSMA and [
resultsBaseline [
conclusionPSMA-PET and [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.